Improving the Application of Shared Decision-Making in the Selection of SLE TreatmentsPremiere Date: Thursday, February 11, 2021
This activity offers CE credit for:%>
- Physicians (CME)
- Pharmacists (ACPE)
- ABIM (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, February 11, 2022
Note: Credit Is No Longer Available
|Allan Gibofsky, MD, JD, MACR, FACP, FCLM (Moderator)
Professor of Medicine
Weill Cornell Medicine
Co-Director, Clinic for Inflammatory Arthritis
Hospital for Special Surgery
New York, NY
|Richard A. Furie, MD
Professor of Medicine, Zucker School of Medicine at Hofstra/Northwell
Chief, Division of Rheumatology, Northwell Health
Great Neck, NY
Patient-reported outcomes (PROs) provide insight into patients' experiences related to their illness, values, preferences, and goals of care and may therefore be useful as predictors of increased risk of mortality in patients with systemic lupus erythematosus (SLE). Due to their ease of use, PROs can be measured easily, quickly, and reliably, especially in communities where access to rheumatologists may be limited. As patients, and their families, prefer to be engaged in their care, it is imperative that clinicians focus on including personalized decision-making, educating patients about their disease and treatment options, and updating them on the progress of their care. However, there continue to be barriers to shared decision-making (SDM) in SLE, including medication risk aversion, prognosis uncertainty, and the financial and administration burdens associated with SLE care.
The final episode in this CMEOCast podcast series on SLE addresses the impact and burden of SLE on quality of life, the integration of PROs when caring for patients with SLE, and the implementation of best practices for SDM in order to engage patients as partners in their care.
At the end of this CE activity, participants should be able to:
- Incorporate SDM into the selection of safe and effective SLE treatments to improve disease outcomes.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Describe ways SDM can be incorporated into the selection of safe and effective SLE treatments to improve disease outcomes.
Supported by an educational grant from AstraZeneca Pharmaceuticals
Rheumatologists, dermatologists, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .25 contact hours (0.025 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to PAs: PAs may claim a maximum of .25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Gibofsky reports that he is on the advisory committee for AbbVie Inc.; Aurinia Pharmaceuticals Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a consultant for AbbVie Inc.; Acquist Therapeutics, Inc.; Amgen Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a stock shareholder (directly purchased) for AbbVie Inc.; Johnson & Johnson; Pfizer Inc.; and Regeneron Pharmaceuticals, Inc.
Dr. Furie reports that he receives research support from Amgen Inc.; AstraZeneca/Medimmune; Biogen Idec; Boehringer-Ingelheim; Bristol-Myers Squibb Company; Eli Lilly and Company; Genentech, Inc./Roche; GlaxoSmithKline; Kezar Life Sciences, Inc.; Nektar Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is a consultant for Alexion Pharmaceuticals, Inc.; AstraZeneca/Medimmune; Biogen Idec; Boehringer-Ingelheim; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Eli Lilly and Company; EMD Serono, Inc.; Equillium, Inc.; Galapagos; Genentech, Inc./Roche; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Kezar Life Sciences, Inc.; MorphoSys US Inc.; Novartis; Reistone Biopharma; Sanofi; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is an investigator for Amgen Inc.; AstraZeneca/Medimmune; Biogen Idec; Boehringer-Ingelheim; Bristol-Myers Squibb Company; Eli Lilly and Company; EMD Serono, Inc.; Equillium, Inc.; Genentech, Inc./Roche; GlaxoSmithKline; Kezar Life Sciences, Inc.; Nektar Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is a committee member for the Lupus Research Alliance and The Lupus Academy.
Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).